Video

Pharmaceutical CEO Leadership: Real-World Evidence

Among the topics discussed at Pharm Exec’s recent RWE roundtable are how the pandemic has served to validate the use of RWE/RWD; the most important features of a real-world data set; and key considerations when selecting an RWD partner.

Read the full article.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
July 31st 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
July 31st 2025

Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson

Don Tracy, Associate Editor
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
July 31st 2025

AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.
What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights
July 31st 2025

What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
July 31st 2025

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Don Tracy, Associate Editor
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
July 31st 2025

Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Don Tracy, Associate Editor
Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.